163 related articles for article (PubMed ID: 16460439)
1. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
2. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
[TBL] [Abstract][Full Text] [Related]
3. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
4. If heparanase is the answer, what is the question?
Rickles FR
J Thromb Haemost; 2006 Mar; 4(3):557-9. PubMed ID: 16460438
[No Abstract] [Full Text] [Related]
5. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
7. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
8. Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis.
Wong SS; Lau WY; Chan PK; Wan CK; Cheng YL
Nephrology (Carlton); 2017 Nov; 22(11):921-924. PubMed ID: 28767200
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
Hardak E; Peled E; Crispel Y; Ghanem S; Attias J; Asayag K; Kogan I; Nadir Y
Thorax; 2020 Feb; 75(2):143-152. PubMed ID: 31892546
[TBL] [Abstract][Full Text] [Related]
10. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
[TBL] [Abstract][Full Text] [Related]
12. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
13. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.
Nadir Y; Brenner B; Fux L; Shafat I; Attias J; Vlodavsky I
Haematologica; 2010 Nov; 95(11):1927-34. PubMed ID: 20634491
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
[TBL] [Abstract][Full Text] [Related]
17. Heparanase coagulation and cancer progression.
Nadir Y; Brenner B
Best Pract Res Clin Haematol; 2009 Mar; 22(1):85-92. PubMed ID: 19285275
[TBL] [Abstract][Full Text] [Related]
18. Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation.
Ham H; Xu Y; Haller CA; Dai E; Stancanelli E; Liu J; Chaikof EL
J Med Chem; 2023 Feb; 66(3):2194-2203. PubMed ID: 36706244
[TBL] [Abstract][Full Text] [Related]
19. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.
Wun TC
Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
